Retatrutide Trial Shows Significant Weight Loss
Recent clinical findings for Eli Lilly’s experimental triple agonist retatrutide show trial participants on the highest 12 mg dose lost between 16.8% and 28.7% of their body weight, prompting widespread attention across obesity medicine. Against this backdrop, Medscape reported that the Endocrine Society issued a scientific statement in September 2026 on the future of obesity medicine, emphasizing that the benefits of treatment extend far beyond weight loss.
The Endocrine Society statement reiterated that obesity functions as a complex, chronic disease influenced by biology, genetics, metabolism, the brain, and environmental factors. The organization highlighted ongoing questions regarding the long-term safety and outcomes of newer obesity medications. Despite these cautions, public discourse often centers on which drug produces the fastest weight reduction, overshadowing the need for individualized, long-term management.
Clinicians Warn of GLP-1 Gastrointestinal Side Effects
While patient demand for GLP-1 receptor agonists remains high, clinicians emphasize that these medications carry significant side effects. The most common adverse events include nausea, vomiting, diarrhea, constipation, and abdominal pain. Low blood sugar can also occur in individuals without diabetes who take these medications for weight management.
Center on Obesity Launch: See What's Next in Obesity Science & Care!Join the official launch of the Endocrine Society’s new Center on Obesity. Get a first look at the new Scientific Statement & explore resources for research and patient care. RSVP: https://t.co/TkfTYoRhhA pic.twitter.com/AhzOUOBH24
Brian Wojeck, MD, MPH, assistant professor of medicine in endocrinology at the Yale School of Medicine in New Haven, Connecticut, cautioned Medscape Medical News that these therapies require careful patient discussion. “GLP-1s are not benign medicines,” Wojeck said, noting a theoretical risk of medullary thyroid carcinoma alongside gastrointestinal motility slowing. He advises patients experiencing severe abdominal pain to stop taking the medication immediately and visit an emergency department to check for conditions such as cholecystitis and pancreatitis.
Rapid weight loss does not always equate to fat reduction or improved health. Amy Joy Sheer, MD, MPH, program director for the Obesity Medicine Fellowship at the University of Florida College of Medicine in Gainesville, told Medscape Medical News that clinicians must monitor patients closely. “If someone is becoming frail, losing strength, struggling to eat enough, or having significant side effects, that is a reason to reassess,” Sheer said.
Personalized Obesity Management Plans
Experts advocate for a holistic view of obesity treatment rather than focusing exclusively on the bathroom scale. Abd Tahrani, honorary professor of medicine at the University of Birmingham in England and head of global development obesity and related conditions at Amgen, emphasized the chronic nature of the condition. “I encourage patients to think about obesity treatment not simply in terms of reaching a particular number on the scale, but as sustained, long-term disease management,” Tahrani said.
According to guidance from the British National Institute for Health and Care Excellence, treatment should begin with a patient-physician discussion regarding weight concerns and related health issues. Tahrani noted that shared decision-making helps establish personalized treatment goals that target broader health outcomes.
Clinicians also recommend lifestyle measures to support metabolic health during treatment. Sheer advises patients to use body mass index as a screening tool rather than a finish line, focusing instead on energy levels, diabetes control, and reduced joint pain. Wojeck stresses that weight-bearing exercises and adequate protein intake are necessary to preserve muscle mass, as walking alone is generally insufficient.
Related reading